Showing 6001-6010 of 6778 results for "".
- Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitishttps://practicaldermatology.com/news/glenmark-pharmaceuticals-reports-positive-phase-2a-data-for-gbr-830-for-atopic-dermatitis/2458102/Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, i
- Cutanea Life Sciences Unveils Facing Forward Mobile App for Acne Patientshttps://practicaldermatology.com/news/cutanea-life-sciences-unveils-facing-forward-new-mobile-app-for-acne-patients/2458104/Cutanea Life Sciences, Inc. introduced its Facing Forward mobile application for patients who are prescribed Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The app will be available free thro
- Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humirahttps://practicaldermatology.com/news/boehringer-ingelheim-begins-interchangeability-study-between-adalimumab-biosim-and-humira/2458106/The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40 mg/0.8 ml. This is the first study in the U.S. to investigate an interchange
- Innovation in Action: Meet the DNA Sunscreen that Gets Better the Longer You Wear Ithttps://practicaldermatology.com/news/innovation-in-action-meet-a-dna-sunscreen-that-gets-better-the-longer-you-wear-it/2458109/Researchers at Binghamton University, State University of New York have developed a coating made out of DNA that gets better at protecting skin from Ultraviolet light the more you expose it to the sun, and it also keeps your skin hydrated. “Ultraviolet (UV) light can actually damage
- Joseph H. Boccuzi Appointed to Allergan plc Board of Directorshttps://practicaldermatology.com/news/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors/2458116/Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Valeant to Sell Obagi Medical Products Business for $190 Mhttps://practicaldermatology.com/news/valeant-to-sell-obagi-medical-products-business-for-190-m/2458117/Valeant Pharmaceuticals International, Inc. has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic ma
- FOREO's New At-Home Blue Light Acne Pen Hits the US and Canadahttps://practicaldermatology.com/news/foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada/2458129/FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESP
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- FDA Approves SciBase's Nevisense for Melanoma Detectionhttps://practicaldermatology.com/news/fda-approved-scibases-nevisense-for-melanoma-diagnosis/2458136/The FDA has approved the Scibase Pre-Market Approval (PMA) for Nevisense, a device for the early detection of malignant melanoma. According to the letter from the FDA the device is intended for use on cutaneous lesions with one or more clinical or historical characteristics of melano